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Abstract
Introduction: The endothelium is considered as a target for the prevention and treatment of pathological processes 
leading to cardiovascular diseases.
Materials and methods: Endothelial dysfunction was simulated in male rats using an e-NOS inhibitor L-NAME 
(25 mg/kg/day intraperitoneally, 7 days). This pathology was then corrected by administering mexidol  at a dose of 
60 mg/kg and L-norvaline at a dose of 10 mg/kg, as well as the combination of both at the same doses, intragastrically, 
through an atraumatic probe, once a day.
Results and discussion: A combination of L-norvaline at a dose of 10 mg/kg and mexidol at a dose of 60 mg/kg against 
the background of L-NAME-induced endothelial dysfunction has a pronounced endothelial protective effect. This is 
reflected in the prevalence of endothelial-dependent vascular relaxation, a significant decrease in the coefficient of 
endothelial dysfunction, as well as the prevention of a decline in the concentrations of stable nitric oxide metabolites 
and of a decrease in the level of the inflammatory changes marker in the vascular wall. The combination of L-norvaline 
and mexidol, with different pathogenetic action mechanisms, has a pronounced endothelial protective effect because of 
their antioxidant properties (mexidol) and donation of nitric oxide (L-arginine).
Conclusion: The investigated drugs showed pronounced endothelial protective activity and can be recommended for 
further pre-clinical studies.
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Introduction
The discovery of an active role of the endothelium has led 
to significant progress in the field of vascular research.
It is known that endotheliocytes have a pronounced 
metabolic activity and synthesize substances that pro-
vide: atrombogenicity and thrombogenicity of the vascu-
lar wall, regulation of the vascular wall adhesion, regu-
lation of vascular tone and regulation of vascular growth 
(Félétou and Vanhoutte 2006).
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The impaired synthesis of nitric oxide (NO) results in 
changes of the vasoregulating function of the endotheli-
um, followed by vasoconstriction.
The barrier role of the vascular endothelium as an ac-
tive organ determines its main role in the human body: 
maintaining homeostasis by regulating the equilibrium 
state of opposite processes – vascular tone (vasodilation/
vasoconstriction), anatomical structure of the vessels 
(synthesis/inhibition of proliferation factors), hemosta-
sis (synthesis and inhibition of fibrinolysis factors and of 
platelet aggregation), and local inflammation (production 
of pro- and anti-inflammatory factors).
The manifestation of failure of any of these functions 
leads to a violation of the integral regulation of peripheral 
blood flow, which in clinical practice corresponds to the 
established term “endothelial dysfunction” (ED).
Endothelial dysfunction is considered as a predictor of 
a number of diseases, including hypertension, coronary 
heart disease, chronic heart failure, as well as a pathoge-
netic component of organ damage in diabetes, hypoestro-
genic and several other pathological conditions (Félétou 
and Vanhoutte 2006).
In cardiovascular diseases, the ability of endothelial 
cells to release relaxing factors decreases, and the forma-
tion of vasoconstrictors is maintained or increased, i.e. an 
imbalance is formed between the mediators. These nor-
mally ensure the optimal course of all endothelium-de-
pendent processes, such as relaxation and constriction, 
anti- and pro-thrombogenesis, antiproliferation and prolif-
eration. The main mechanisms in the development of ED 
are the insufficient production of nitric oxide (Félétou and 
Vanhoutte 2006), as well as the impaired synthesis of NO, 
which results in changes of the vasoregulating function of 
the endothelium, and is finally followed by vasoconstric-
tion. Nitric oxide is involved in the regulation of almost 
all endothelium functions, and, moreover, is the factor 
most sensitive to damage. The most important factor in 
the disruption of the formation and/or of bioavailability of 
nitric oxide is the excessive formation of reactive oxygen 
species (ROS), which is observed in many diseases (Först-
ermann at al. 2017, Mason 2016). Nitric oxide inhibits 
adhesion, platelet aggregation and the growth of a form-
ing thrombus. It can stimulate angiogenesis, which is po-
tentially important in conditions of myocardial ischemia 
(Chernomortseva et al. 2010, Pokrovsky et al. 2008).
Endothelial dysfunction associated with the impaired 
nitric oxide production is one of the initial metabolic dis-
orders in the development of cardiovascular diseases. NO 
is formed from the amino acid L-arginine. Metabolism of 
L-arginine in cells proceeds in two ways. L-arginine is 
hydrolyzed by arginase to ornithine and urea. The other 
way of converting L-arginine to nitric oxide and citrulline 
is catalyzed by NO-synthase. The enzymes of arginase 
and NO-synthase compete with each other for the com-
mon substrate L-arginine (Johnson et al. 2005, Zhu et al. 
2017). An increase in the activity of the arginase enzyme 
leads to a decrease in the formation of the main vasodi-
lator – NO, that is, to the development of ED (Belenkov 
et al. 2009, Pokrovsky et al. 2008, Tsepeleva et al. 2011, 
Xiong et al. 2014).
The use of arginase inhibitors is currently considered 
one of the promising ways to correct ED. Their mech-
anism of action is to block the enzyme arginase, and, 
consequently, to disturb the conversion of L-arginine into 
ornithine and urea. As a result, more L-arginine is cleaved 
by the action of NO synthase to form nitric oxide. Thus, 
arginase inhibitors prevent the development of nitric 
oxide deficiency, as one of the most important etiolog-
ical factors of endothelial dysfunction (Poljanskaja and 
Pokrovsky 2014).
Arginase inhibitors can be selective and non-selective. 
Some of the arginase inhibitors have already been studied 
in vitro. The least studied in the group of non-selective 
arginase inhibitors is L-norvaline (Tsepeleva et al. 2011).
In this regard, the correction of free radical processes 
in ED is extremely important, since it makes it possible 
to prevent the accelerated degradation of NO, to restore 
the activity of NO synthase, to express NO in the blood-
stream and to prevent the development of endothelial dys-
function (Bulakhova 2006).
The basis of disorders leading to endothelial dysfunc-
tion is the change in the production of biologically ac-
tive compounds synthesized by vascular endothelial cells 
(EC), among which reactive oxygen species are of great-
est importance, from the point of view of the problem un-
der consideration (Chernomortseva et al. 2010, Sibal et 
al. 2010, Ragulina 2017). This group of highly reactive 
molecules includes molecular oxygen and a number of its 
derivatives, which are formed in all aerobic cells.
Excessive reactive oxygen species cause significant 
changes in the function of the vascular endothelium, for 
example; inhibition of endothelium-dependent vasodilation 
and an increase in the synthesis of adhesive molecules leads 
to adhesion and penetration of monocytes into the vascu-
lar wall, turning them into macrophages; an increase in the 
production of various growth factors, an increase in plate-
let aggregation and thrombus formation, apoptosis activity, 
etc. In general, severe dysfunction of the vascular endothe-
lium occurs (Félétou and Vanhoutte 2006, Mason 2016).
A promising antioxidant drug is a 3-hydroxypyridine 
derivative mexidol, which regulates metabolic processes 
in the myocardium and the vascular wall. It reduces the 
manifestations of oxidative stress, inhibits free radical lipid 
peroxidation and increases the activity of the antioxidant 
system of enzymes (Bulakhova 2006, Ragulina 2017).
An integrated practical treatment of impaired endothe-
lial functions may be of great practical interest when ther-
apy combines drugs that affect several pathogenetic links 
of endothelial dysfunction development.
Aim of the study
To study the endothelil protective effects of the combina-
tion of an arginase inhibitor L-norvaline and antioxidant 
mexidol.
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Materials and methods
The experiments were performed on 70 Wistar male rats 
(250 ± 50 g), in compliance with the requirements of the 
federal law of the Russian Federation On Protection of 
Animals Against Cruel Treatment dated June 24, 1998, the 
rules of laboratory practice in preclinical studies in the Rus-
sian Federation (GOST 3 51000.3-96 and GOST R 53434-
2009), European Community directives (86/609 EU), the 
rules and the international recommendations of The Euro-
pean Convention for the Protection of Vertebrate Animals 
Used in Experimental Studies (1997) and The Laboratory 
Practice Rules adopted in the Russian Federation (order of 
the Ministry of Healthcare of the Russian Federation No. 
708 of August 29, 2010) (GOST 33044-2014 2015).
Simulation of endothelial dysfunction was performed 
by injections of the NO-synthase inhibitor N-nitro-L-ar-
ginine methyl ester (L-NAME, Sigma) to males intraperi-
toneally once a day at a dose of 25 mg/kg for seven days. 
The animals of the intact group were injected with saline 
(0.9% NaCl) in the same volume (Pokrovsky et al. 2006).
The following experimental groups of male rats were 
formed: 1) intact – (n = 10); 2) group of L-NAME-induced 
deficiency of nitrogen oxide (n = 10); 3) L-NAME+L-nor-
valine10 mg/kg (n = 10); 4) L-NAME+mexidol 60 mg/
kg (n = 10); 5) L-NAME+L-norvaline10 mg/kg+mexidol 
60 mg/kg (n = 10).
L-norvaline and mexidol, as well as their combination, 
were injected to the experimental animals intragastrically 
daily (through an atraumatic probe) at a dose of 10 mg/kg/
day and 60 mg/kg/day against the injection of L-NAME 
to them.
Functional vascular and cardiac tests were performed 
by insertion of a catheter into the left carotid artery of the 
rats to record hemodynamic parameters on the 8th day of 
the experiment. The animals were at that moment under 
anesthesia. Bolus dosing of vascular and cardiac samples 
was in the right femoral vein. The hemodynamic param-
eters, namely, systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and heart rate (HR) were measured 
continuously by means of a TSD104A sensor and a Bi-
opac MP150 system. Acetylcholine (40 µg/kg) was inject-
ed intravenously to determine endothelium-dependent va-
sodilatation (EDV), and sodium nitroprusside (30 µg/kg) 
was injected intravenously to determine endothelium-in-
dependent vasodilation (ENDV) (Pokrovsky et al. 2006).
The coefficient of endothelial dysfunction (CED) was 
calculated as the ratio of the area of the triangle above 
the blood pressure (BP) recovery curve in the endothe-
lium-independent vasodilation to the area of the triangle 
above the BP recovery curve in the endothelium-depend-
ent vasodilation in terms of mean arterial pressure.
On the model of L-NAME-induced ED after vascular 
samples, myocardial contractility was studied in anesthe-
tized males in controlled breathing. The left ventricular 
cavity was accessed with a needle through the apex of the 
heart, the left ventricular pressure was recorded by means 
of a TSD104A sensor of L-154 ADC and a Biopac MP150 
system; stress tests were performed to measure adrenaline 
reactivity (by injecting adrenaline intravenously 1·10–
5 mol/L in volume of 0.1 ml/100 g per body weight) and 
load resistance (by compressing the ascending part of the 
aortic arch for 30 seconds) (Pokrovsky et al. 2008).
The total nitrates and nitrites were measured in one step 
by using a modified method (Metelskaya et al. 2004). The 
level of C-reactive protein was determined by immunotur-
bodimetric measurement at a wavelength of 340 nm, by 
means of nonlinear calibration using HUMAN reagents 
(Germany) on a Vitalab Flexor biochemical analyzer.
The data obtained as a result of the research was pro-
cessed statistically, using parametric and non-parametric 
methods. The significance of differences in the mean val-
ues in the case of a normal distribution in two samples 
was evaluated by Student’s t-test, in the case of an abnor-
mal distribution – by Wilcoxon test. In order to identify 
hidden factors affecting statistical correlations, a factor 
analysis was carried out, using the method of basic com-
ponents. Differences at p < 0.05 were recognized as sta-
tistically significant. Statistical processing was performed 
using MS Excel and Statistica 10 software (Glants 1999).
Results and discussion
The effect of L-norvaline and mexidol, as well as their 
combined use at doses of 10 mg/kg and 60 mg/kg, respec-
tively, on the baseline blood pressure indicators in anes-
thetized rats with L-NAME-induced pathology simulati-
on are presented in Table 1.
A seven-day administration of L-NAME, according 
to the above scheme, was found to cause arterial hyper-
tension 190.3 ± 6.7/145.0 ± 3.9 mmHg. Processing the 
experimental data obtained when performing functional 
tests for endothelium-dependent and endothelium-inde-
pendent vascular relaxation in the experimental animals 
made it possible to establish a 5-time increase in CED in 
the group with NO-synthase blockade (Fig. 1).
The values of indicators of SBP and DBP in the group of 
intact animals were considered as the target values of blood 
pressure. The studied drugs prevented the development of 
severe hypertension. The values of SBP and DBP were sig-
nificantly lower than the corresponding values of the ani-
mals with L-NAME-simulated pathology. The experiment 
revealed that the combined use of L-norvaline and mex-
idol, in contrast to monotherapies with these drugs, had a 
hypotensive effect, which was significantly different from 
that in the animals treated with monotherapies with these 
substances against the background of L-NAME.
The results of functional tests for endothelium-depend-
ent (acetylcholine 40 µg/kg) and endothelium-independ-
ent (Sodium nitroprusside 30 µg/kg) vascular relaxation 
in animals with L-NAME-induced pathology with the 
combined therapy with mexidol (60 mg/kg) and L-norva-
line (10 mg/kg) made it possible to establish their signif-
icant endothelial protective effect, which was expressed 
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Table 1. Model of L-NAME-induced NO Deficiency. Changes in Hemodynamics and Functional Tests When Using a Combination 
of L-norvaline (10 mg/kg) and Mexidol M (60 mg/kg) Against the Background of L-NAME-induced Simulation of Endothelial 
dysfunction (M ± m, n = 10).
Group of animals Functional test SBP, mmHg DBP, mmHg HR, b/min
Intact Source data 137.7 ± 3.7 101.9 ± 4.3 453.8 ± 11.6
Acetylcholine 84.3 ± 4.5 38.7 ± 2.8 448.3 ± 11.0
Sodium nitroprusside 83.0 ± 3.7 42.1 ± 4.4 464.1 ± 11.5
L-NAME (25 mg/kg) Source data 190.3 ± 6.7* 145.0 ± 3.9* 417.0 ± 11.7
Acetylcholine 110.6 ± 5.2* 82.8 ± 6.6* 399.8 ± 15.6*
Sodium nitroprusside 88.7 ± 4.7 50.8 ± 4.2 401.7 ± 11.8
L-NAME (25 mg/kg)+ L-norvaline (10 mg/kg) Source data 180.0 ± 4.7* 144.6 ± 5.1* 371.4 ± 11.0**
Acetylcholine 106.7 ± 4.9* 56.1 ± 1.8** 344.2 ± 15.0**
Sodium nitroprusside 129.3 ± 5.1** 64.6 ± 2.5* 358.3 ± 12.0**
L-NAME (25 mg/kg)+ mexidol (60 mg/kg) Source data 168.1 ± 1.3* 135.6 ± 1.2* 361.3 ± 8.1**
Acetylcholine 80.4 ± 2.6** 51.3 ± 4.3** 353.0 ± 6.9**
Sodium nitroprusside 80.7 ± 5.1* 45,7 ± 2.0* 379.2 ± 7,3**
L-NAME (25 mg/kg)+ L-norvaline (10 mg/kg)+ mexidol (60 мг/кг) Source data 160.2 ± 1.5** 131.0 ± 3.5* 399.0 ± 19.0**
Acetylcholine 85.5 ± 3.5** 62.6 ± 3.6** 346.1 ± 10.0**
Sodium nitroprusside 87.4 ± 4.7* 51.8 ± 4.6* 357.4 ± 12.0**
Note: SBP – systolic blood pressure, DBP – diastolic blood pressure, HR – heart rate; * – p < 0.05 – in comparison with intact animals, ** – p < 0.05 
– in comparison with L-NAME.
in the predominance of endothelium-dependent vascular 
relaxation (Fig. 1).
At the same time CED decreased to 1.4 ± 0.2 c.u., 
which was significantly different from a monotherapy 
with mexidol (2.9 ± 0.2 c.u.). It is noteworthy that this 
is somewhat better than with a L-norvaline monotherapy 
(2.1 ± 0.2 c.u.).
In combination with the information described above 
about the beneficial effect of the combined use of an arginase 
inhibitor L-norvaline and a synthetic antioxidant mexidol 
on the original blood pressure indicators, the data obtained 
indicate the effectiveness of the combined use of L-norva-
line with mexidol for the correction of L-NAME-induced 
pathology, which allowed a moderate decrease in blood 
pressure values, along with effective CED reduction.
When conducting functional stress-tests on the mod-
el of L-NAME-induced NO deficiency, there was an in-
crease in the absolute values of left ventricular pressure in 
the adrenoreactivity test to 247.3 ± 4.8 mm Hg, which was 
significantly higher than the values of the intact animals. 
The use of the combination of L-norvaline (10 mg/kg) and 
mexidol (60 mg/kg) contributed to the prevention of an 
increase in adrenoreactivity caused by L-NAME-induced 
pathology (Tab. 2).
A decrease in myocardial reserve was recorded in the 
test for load resistance. In the intact males, the left ven-
tricular pressure decreased to 83.6 ± 2.1% by the 25th sec-
ond of the aortic compression, and in the animals with 
L-NAME-induced ED – to 66.0 ± 3.2% (Table 2). Using 
the combination of mexidol and L-norvaline leads to an 
increase in myocardial reserve.
The introduction of an endothelial NO-synthase block-
er L-NAME caused a disturbance in the synthesis of nitric 
oxide (nitrite ions (NOx) concentration is 2.3 ± 0.7 μmol/l), 
and the combination of the drugs restored the level of NO 
necessary for normal functioning of endothelium.
The concentration of nitrite ions under the influence of 
the combined use of L-norvaline and mexidol increased to 
5.8 ± 0.4 μmol/l and was not statistically and significantly 
different from those of intact animals – 7.2 ± 0.6 μmol/l.
Monotherapies with L-norvaline and mexidol also led 
to an increase in NOx concentration in serum to 4.3 ± 
0.6 and 4.7 ± 0.3 μmol/l, respectively, but not as much 
as when compared with the combination of the drugs. 
The results obtained on the NO-producing function of the 
endothelium make it possible to suggest that both drugs 
have an impact on preventing a decrease in the concentra-
tion of nitrite ions NOx in plasma of the laboratory ani-
mals under L-NAME-induced NO deficiency.
In addition to the positive effects of drugs aimed at in-
creasing the level of nitric oxide, the study conducted also 
proved an anti-inflammatory component of their endothe-
lial protective action. The level of the most important reg-
ulator of inflammatory and immune processes – C-reac-
tive protein (CRP) in plasma in the intact group was 0.4 ± 
0.1 mg/dl. Simulation of nitric oxide deficiency naturally 
increased the level of CRP to 2.4 ± 0.2 mg/dl. The intro-
duction of L-norvaline resulted in a decrease in the level 
of this cytokine, which was 0.9 ± 0.1 mg/dl. It is notewor-
Figure 1. Effect of mexidol and L-norvaline on CED of male 
rats in the simulation of L-NAME-induced NO deficiency 
(M±m). Note: * – p < 0.05 compared to the intact rats; у – p < 
0.05 compared to the L-NAME group of animals; СED – coeffi-
cient of endothelial dysfunction.
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thy that mexidol, both in the form of monotherapy and in 
combination with L-norvaline, significantly reduced the 
concentration of CRP in the blood of the experimental an-
imals to 0.6 ± 0.1 mg/dl with the same efficiency. The lat-
ter suggests that it is mexidol that has the main influence 
on reducing the concentration of CRP.
Recent years have been marked by the intensive devel-
opment of fundamental and clinical research on the role of 
the vascular endothelium in the genesis of cardiovascular 
diseases (CVD). A theoretical basis was created for a new 
direction of fundamental and clinical research – to study 
the role of endothelial dysfunction in the pathogenesis of 
CVD and to search for ways to effectively correct it (Be-
lenkov et al. 2009, Chernomortseva 2010, Ragulina 2017).
The main objective of the current study was to investigate 
the possibility of correcting L-NAME-induced endothelial 
dysfunction in the experiment by combining the arginase in-
hibitor L-norvaline with the synthetic antioxidant mexidol.
Monotherapy with the tested drugs did not increase 
the blood pressure indicators to a given level and, there-
fore, mexidol and L-norvaline cannot be considered as 
monotherapy on a model with L-NAME-induced arterial 
hypertension.
The initial levels of blood pressure when simulating 
L-NAME-induced arterial hypertension were significant-
ly lower than in the groups with L-norvaline and mex-
idol monotherapies, which suggests that the basis of the 
proposed endothelioprotective effect on the two different 
pathogenetic links.
On the one hand, mexidol inhibits free radical oxida-
tion, activates superoxide dismutase, increases the con-
tent of polar fractions of lipids in the membrane, reduces 
the viscosity of the lipid layer, increases the membrane 
fluidity, activates the energy exchange in the cell and thus 
protects the NO-synthase, increasing nitric oxide produc-
tion (Belenkov et al. 2009, Bulakhova 2006, Ragulina 
2017, Siasos at al. 2018).
On the other hand, L-norvaline inhibits the enzyme that 
destroys the substrate for the formation of nitric oxide, and 
compensates for violations of NO production in the endothe-
lium (Tsepeleva et al. 2011). L-novaline also exhibits its 
protective effects due to its ability to inhibit the ribosomal 
protein kinase S6K1 involved in the synthesis of adhesion 
molecules, in particular E-selectin, VCAM-1 and ICAM-1, 
inhibiting the formation of thromboxane A2 and platelets, fi-
brin complex, accelerating the plasmin formation and fibrin 
destruction, reducing blood viscosity; reducing the formation 
of free radicals and ensuring their removal from endothelial 
cells (Mason 2016, Poljanskaja and Pokrovsky 2014).
The results of the experiments conducted in the pres-
ent study indicate that the combination of mexidol and 
L-norvaline has a pronounced therapeutic effect in the res-
toration of the endothelial regulatory function and helps 
to restore the activity of NOS synthase, as judged by an in-
crease in the concentration of total nitrate and nitrite ions, 
which are final metabolites of nitric oxide (Bulakhova 
2006, Tsepeleva et al. 2011). This can be due to an increase 
in the bioavailability of NO, since antioxidants, as well 
as a reduced oxidative stress, prevent the degradation of 
nitric oxide, while blocking arginase leads to an increase 
in the endogenous synthesis of L-arginine and the resto-
ration of NO production (Bulakhova 2006, Poljanskaja 
and Pokrovsky 2014). In addition to the positive effects of 
L-norvaline and mexidol aimed at increasing the level of 
nitric oxide, the present study also proved the anti-inflam-
matory component of their endothelioprotective action.
The above aspects of this problem can serve as a basis 
for the development of new preventive and therapeutic 
measures to be used in addition to the existing methods of 
treating cardiovascular diseases.
Monotherapy with L-norvaline and mexidol showed 
significantly less pronounced endothelioprotective proper-
ties than the combined use of these drugs. Thus, the com-
bined use of a non-selective arginase inhibitor L-norvaline 
and a synthetic antioxidant mexidol to achieve endothelial 
protective effects should be considered as more efficient. 
This, in turn, make it possible to recommend a wide clini-
cal study to be conducted due to the pathogenetically jus-
tified effects on the antioxidant and antiarginase systems.
Conclusion
The combination of L-norvaline at a dose of 10 mg/kg 
and mexidol at a dose of 60 mg/kg against the background 
of L-NAME-induced endothelial dysfunction has a pron-
ounced endothelial protective effect. It is reflected in the 
prevalence of endothelial-dependent vascular relaxation 
and a significant decreasing of the Coefficient of endo-
thelial dysfunction, as well as in preventing the decline 
of concentrations of nitric oxide stable metabolites and a 
decrease in the level of the inflammatory changes marker 
in the vascular wall.
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Table 2. Effect of Using Mexidol and L-norvaline on Functional Parameters in Male Rats When Simulating L-NAME-induced NO 
Deficiency (M±m).
Indicator Intact L-NAME L-NAME+ L-norvaline 
10 mg/kg
L-NAME+ mexidol 60 
mg/kg
L-NAME+ L-norvaline 10 
mg/kg+ mexidol 60 mg/kg
ADR, mmHg 199.2 ± 8.3 247.3 ± 4.8* 239.6 ± 2.2** 220.2 ± 5.2** 191.4 ± 8.5**
LR, % 83.6 ± 2.1 66.0 ± 3.2* 87.6 ± 1.1** 84.2 ± 1.3** 91.0 ± 4.5**
Note: ADR – adrenoreactivity, LR – load resistance. * – p < 0.05 compared with the intact group of animals; ** – p < 0.05 compared with L-NAME 
group of animals.
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